Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mocetinostat + Durvalumab in Advanced Solid Tumors and NSCLC
NCT02805660Phase 2Terminated
- Sponsor
- Mirati Therapeutics
- Start
- Jun 2016
- Primary completion
- Dec 2019
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of mocetinostat in solid tumor, non-small cell lung cancer (NSCLC), sponsored by Mirati Therapeutics. Started Jun 2016; status: terminated.
02
Drugs
mocetinostat
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02805660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02805660.